Virtual Library
Start Your Search
Daniel Morgensztern
Author of
-
+
FP07 - Pathology (ID 109)
- Event: WCLC 2020
- Type: Posters (Featured)
- Track: Pathology, Molecular Pathology and Diagnostic Biomarkers
- Presentations: 1
- Moderators:
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
FP07.13 - Clinical Characteristics and Outcomes in Patients With KRAS G12C Mutated Non-Small Cell Lung Cancer (ID 1415)
00:00 - 00:00 | Author(s): Daniel Morgensztern
- Abstract
Introduction
KRAS oncogenic mutations are the most common driver alterations in non-small cell lung cancer (NSCLC). Among these, G12C mutations are the most frequently encountered and targetable with currently available investigational therapies. Understanding the clinical characteristics and outcomes in patients with G12C mutated NSCLC has the potential to inform clinical testing in resource limited settings and facilitate the study of novel combination therapies.
Methods
KRAS-mutant NSCLC patients treated at Washington University in St. Louis were retrospectively identified through review of commercial target hybrid-capture next generation sequencing (NGS) test results (plasma and tissue). Clinical and demographic information was collected from electronic medical records. Patients were categorized into two groups based on the KRAS mutation: G12C and non-G12C. Fisher’s exact test was used for comparing categorical variables and log-rank test was used to test for differences in survival, between these categories.
Results
A total of 169 patients with KRAS mutations were identified for this study. Nearly a third of patients were G12C mutated (n=64,37.6%) (Table 1). The majority of patients in both groups were diagnosed with stage IV disease (68.7% [G12C] and 72.9% [non-G12C]). PD-L1 (22C3 antibody) status was available in 43.7% of patients and PD-L1 status did not significantly differ between both categories (p=0.772). G12C mutations were observed in patients of all races and predominantly in smokers (96.9%). Apart from adenocarcinomas (92.2%), G12C mutations were also observed in large cell carcinomas (n=5), poorly differentiated carcinomas (n=3), NSCLC-NOS (n=1) and combined adenocarcinoma-small cell lung cancer (n=1). Pattern of metastasis at presentation did not differ between G12C and non-G12C patients. Overall, 28 KRAS mutated patients received immunotherapy as single agent or in combination with chemotherapy in the first-line setting (n=10 [G12C] and n=18 [non-G12C]). While no statistically significant difference in PFS and OS were found between these categories (median PFS 6.24 [G12C] vs 6.27 months [non-G12C], log rank p=0.899; median OS 21.0 [G12C] vs 21.8 months [non-G12C], log rank p=0.992), G12C mutated NSCLC was associated with a better PFS than non-G12C NSCLC (p=0.0384), when the analysis was restricted to patients achieving a durable response to immunotherapy (PFS>3.5 months, corresponding to first 4 cycles).
ConclusionTABLE 1. Patients Characteristics
Characteristic
KRAS G12C (n=64)
Non-KRAS G12C (n=105)
p-valuea
Median Age (range)
64.5 (47-89)
63.0 (46-89)
Gender, n (%)
0.626
Male
22 (34.4)
40 (38.1)
Female
42 (65.6)
65 (61.9)
Race, n (%)
0.156
Caucasian
54 (84.4)
82 (78.1)
African American
7 (10.9)
22 (21.0)
Asian
2 (3.1)
1 (1.0)
Hispanic
1 (1.6)
0 (0)
Smoking history, n (%)
0.08
Ever
62 (96.9)
94 (89.5)
Never
2 (3.1)
11 (10.5)
Histology, n (%)
0.146
Adenocarcinoma
59 (92.2)
83 (77.6)
Squamous cell
0 (0)
6 (5.6)
Large cell
5 (8.0)
18 (16.8)
NSCLC-NOS
3 (4.7)
10 (9.5)
Sarcomatoid
0 (0)
3 (2.9)
Poorly differentiated carcinoma
1 (1.6)
0 (0)
Adenosquamous
0 (0)
1 (1.0)
NSCLC with NET differentiation
0 (0)
1 (1.0)
Adenocarcinoma with SCLC component
1 (1.6)
0 (0)
Carcinoma of the lung
0 (0)
1 (1.0)
Clinical stage*, n (%)
0.942
I
6 (9.3)
8 (7.4)
II
4 (6.4)
5 (4.8)
III
10 (15.6)
16 (14.9)
IV
44 (68.7)
78 (72.9)
PD-L1 status, n (%)
0.704
<1%
13 (20.3)
20 (19.0)
1-49%
7 (10.9)
11 (10.5)
>50%
11 (17.2)
12 (11.4)
Missing
33 (51.6)
62 (59.0)
Initial Therapy, n (%)
0.772
Surgery +/- Chemotherapy
10 (18.2)
12 (12.9)
Radiation
5 (9.1)
9 (9.7)
Concurrent chemoradiation
7 (12.7)
14 (15.1)
Chemoimmunotherapy
6 (10.9)
12 (12.9)
Platinum-doublets
14 (25.5)
27 (29.0)
Pembrolizumab
4 (7.3)
6 (6.5)
Docetaxel
1 (1.8)
0 (0)
Vinorelbine
0 (0)
1 (1.1)
Gemcitabine
0 (0)
1 (1.1)
Pemetrexed
6 (10.9)
7 (7.5)
Targeted therapy
0 (0)
3 (3.2)
Clinical Trial
2 (3.6)
1 (1.1)
aFisher’s exact test p-value; NSCLC-NOS: non-small cell lung cancer, not otherwise specified; NET: neuroendocrine tumor; SCLC: small cell lung cancer; *stage at diagnosis; PD-L1: programmed death ligand-1
Although outcomes and demographics in KRAS G12C and non-G12C mutant NSCLCs appear to be largely comparable, our analyses suggest an association between the presence of G12C mutations and durable responses to immunotherapy. These findings will require validation in larger, prospective studies.
-
+
P09 - Health Services Research/Health Economics - Real World Outcomes (ID 121)
- Event: WCLC 2020
- Type: Posters
- Track: Health Services Research/Health Economics
- Presentations: 1
- Moderators:
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P09.26 - Cause of Death in Patients with Squamous Cell Lung Cancer (SCC) Treated with Surgery (ID 2335)
00:00 - 00:00 | Author(s): Daniel Morgensztern
- Abstract
Introduction
In patients with early stage squamous cell lung cancer (SCC), the standard of care treatment includes surgical resection followed by adjuvant chemotherapy (CT) in those with tumors greater than or equal to 4 cm or with lymph node involvement. Although large randomized studies report overall and relapse-free survival, there is limited data on the cause of death (COD), particularly within the first 12 months from diagnosis. The purpose of this study is to evaluate the survival and COD among patients with SCC treated with surgery.
Methods
The Surveillance, Epidemiology and End Report (SEER) was queried for patients with SCC stage I to IIIA according to AJCC 7th edition, diagnosed between 1998 and 2016, treated with surgery with or without chemotherapy. Outcomes were subdivided into alive, death from lung cancer, death from another type of cancer, death from non-cancer causes and unknown.
Results
There were 26,530 patients (pts) that met the inclusion criteria, of which 16,757 (63.2%) died during the study period. The most common COD was lung cancer (9,046 pts, 54.0%), followed by death from other non-malignant causes (5,902 pts, 35.2%), and death from other cancers (1,721 pts, 10.3%). COD was unknown in 88 pts (0.5%). A total of 4,518 patients (17.0% of total pts and 26.9% of deaths) died within one year from diagnosis. Lung cancer was the most common COD within 12 months (2,869; 63.5%) followed by non-malignant causes (1,195; 26.4%), other malignancies (306; 6.7%) and unknown causes (24; 0.5%). The most common known causes of non-malignant deaths within one year were cardiovascular disease (422; 35.3%), chronic obstructive pulmonary disease (267; 22.3%), infection (160; 13.4%) and stroke (72; 6.2%).
Conclusion
In the general population represented by the SEER database, 17% of patients with early stage SCC undergoing surgery die within 12 months from diagnosis. Despite the indication for surgery and chemotherapy based on stage at diagnosis, better selection of patients according to co-morbidities and performance status may decrease the early mortality after treatment with curative intent.
